Akeso, Inc.: Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...
Taiwan News3h
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso is dedicated to transforming the global oncology treatment landscape by establishing new standards of care for cancer patients worldwide. A key element of this mission is the company's "IO 2.0 + ...
Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC ...
中国日报网10h
Chinese company's drug beats world's biggest-selling medicine: media
Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...
You thought only DeepSeek routed American titans? Wait, here's a little-known Chinese biotech company whose lung cancer drug could rattle big pharma; here's al…
Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...